AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula I:

$$R^{6}$$
 R^{4}
 R^{7}
 R^{7}
 R^{4}
 R^{5}
 R^{1}

FORMULA I

wherein R¹ is:

- a) linear or branched alkyl containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom selected from the group consisting of halogen or a nitrogen atom, and/or bearing at least one nitrogen group;
- b) aryl or heteroaryl optionally substituted by an alkyl or aryl group that is optionally substituted with an at least one heteroatom selected from the group consisting of halogen or a nitrogen atom, and/or bearing at least one nitrogen group;
- c) -C(O)R, -C(O)OR, or -CO-NRR', wherein R and R' are independently selected from the group consisting of hydrogen, aryl, heteroaryl, alkyl, and cycloalkyl, each optionally substituted with <u>at least one a heteroatom selected from the group consisting of halogen or a nitrogen atom, and/or bearing at least one nitrogen group;</u>

R² is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;

R³ is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;

R⁴ is halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;

R⁵ is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;

R⁶ is one of the following:

- (i) an aryl group such as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl, and alkoxy;
- (ii) a heteroaryl group such as a 2, 3, or 4-pyridyl group, which may additionally bear any combination of one or more substituents;
- (iii) a five-membered ring aromatic heterocyclic group such as for example 2-thienyl, 3-thienyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, which may additionally bear any combination of one or more substituents;

and R^7 is one of the following:

- (i) an aryl group such as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents;
- (ii) a heteroaryl group such as a 2, 3, or 4-pyridyl group, which may additionally bear any combination of one or more substituents;

- (iii) a five-membered ring aromatic heterocyclic group such as for example 2-thienyl, 3-thienyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, which may additionally bear any combination of one or more substituents;
- (iv) H, a halogen selected from I, F, Cl or Br; NH₂, NO₂ or SO₂-R", wherein R" is a linear or branched alkyl group containing one or more group, and optionally substituted with at least one heteroatom selected from the group consisting of halogen or a nitrogen atom, and/or bearing at least one nitrogen group.

Claims 2-53. (Canceled).

- 54. (Previously Presented) A composition comprising a compound of claim 1 in a pharmaceutically acceptable carrier.
- 55. (Withdrawn) A method for treating a c-kit-mediated disorder in a mammal, comprising administering a compound of Claim 1 to a mammal suffering from such a disorder.
- 56. (Withdrawn) A method according to claim 55 wherein said c-kit-mediated disorder is selected from the group consisting of: neoplastic diseases, mastocytosis, canine mastocytoma, human gastrointestinal stromal tumor ("GIST"), small cell lung cancer, non-small cell lung cancer, acute myelocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, colorectal carcinomas, gastric carcinomas, gastrointestinal stromal tumors, testicular cancers, glioblastomas, and astrocytomas.
- 57. (Withdrawn) A method according to claim 55 wherein said c-kit-mediated disorder is selected from the group consisting of: allergic diseases such as asthma, allergic rhinitis, allergic sinusitis, anaphylactic syndrome, urticaria, angioedema, atopic dermatitis, allergic contact dermatitis, erythema nodosum, erythema multiforme, cutaneous necrotizing venulitis and insect bite skin inflammation and blood sucking parasitic infestation.

- 58. (Withdrawn) A method according to claim 55 wherein said c-kit-mediated disorder is selected from the group consisting of: inflammatory diseases, arthritic conditions, rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, and gouty arthritis.
- 59. (Withdrawn) A method according to claim 55 wherein said c-kit-mediated disorder is selected from the group consisting of: autoimmune diseases, multiple sclerosis, psoriasis, intestine inflammatory disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis and polyarthritis, local and systemic scleroderma, systemic lupus erythematosus, discoid lupus erythematosus, cutaneous lupus, dermatomyositis, polymyositis, Sjogren's syndrome, nodular panarteritis, autoimmune enteropathy, and proliferative glomerulonephritis.
- 60. (Withdrawn) A method according to claim 55 wherein said c-kit-mediated disorder is selected from the group consisting of: graft-versus-host disease and graft rejection.
- 61. (Currently Amended) A compound according to claim 1 selected from the group consisting of:
 - (i) 4-Diethylaminomethyl-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
 - (ii) N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-morpholin-4-ylmethyl-benzamide;
 - (iii) 4-Dipropylaminomethyl-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
 - (iv) N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-piperidin-1-ylmethyl-benzamide;
 - (v) 3-Iodo-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
 - (vi) 4-Hydroxymethyl-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)phenyl]-benzamide;

- (vii) 4-{[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenylamino]-methyl}-benzoic acid methyl ester;
- (ix) (viii) 4-Amino-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (x) (ix) 2-Iodo-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (xi) 4-Iodo-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (xii) 4-(3-{4-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenylcarbamoyl]-phenyl}-ureido)-benzoic acid ethyl ester;
- (xiii) (xii) N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-[3-(4-trifluoromethyl-phenyl)-ureido]-benzamide;
- (xiv) (xiii) 4-[3-(4-Bromo-phenyl)-ureido]-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (xv) (xiv) {4-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)phenylcarbamoyl]-benzyl}-carbamic acid tert-butyl ester;
- (xvi) (xv) 4-Hydroxy-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (xvii) (xvi) 4-[(Diisopropylamino)-methyl]-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (xviii) (xvii) N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-(3-thiophen-2-yl-ureido)-benzamide;
- (xix) (xviii) 4-[3-(3,5-Dimethyl-isoxazol-4-yl)-ureido]-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (xx) (xix) 4-[3-(4-Methoxy-phenyl)-ureido]-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (xxi) (xx) 4-[3-(4-Difluoromethoxy-phenyl)-ureido]-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;

- (xxii) (xxi) Thiophene-2-sulfonic acid 4-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenylcarbamoyl]-phenyl ester;
- (xxiii) (xxii) 4-Iodo-benzenesulfonic acid 4-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenylcarbamoyl]-phenyl ester;
- (xxiv) (xxiii) N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-pyrrolidin-1-ylmethyl-benzamide;
- (xxiv) 3-Methyl-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]benzamide;
- (xxvi) (xxv) N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;
- (xxvii) (xxvi) 4-[3-(2,4-Dimethoxy-phenyl)-ureido]-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (xxviii) N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-[3-(4-trifluoromethyl-phenyl)-ureidomethyl]-benzamide;
- (xxix) (xxviii) 4-[3-(2-Iodo-phenyl)-ureido]-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (xxx) (xxix) 4-[3-(4-Fluoro-phenyl)-ureido]-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (xxxi) (xxx) 2-Fluoro-benzenesulfonic acid 4-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenylcarbamoyl]-phenyl ester;
- (xxxii) (xxxi) 3-Fluoro-benzenesulfonic acid 4-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenylcarbamoyl]-phenyl ester;
- (xxxiii) (xxxiii) 2-(2-methyl-5-tert-butoxycarbonylamino)phenyl-4-(3-pyridyl)-thiazole,
- (xxxiv)(xxxiii) 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole;
- (xxxv) (xxxiv) 4-(4-Methyl-piperazin-1-ylmethyl)-N-[3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;

- (xxxvi)(xxxv) N-[4-Methyl-3-(4-phenyl-thiazol-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide;
- (xxxvii) (xxxvi)N-[3-([2,4']Bithiazolyl-2'-ylamino)-4-methyl-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide;
- (xxxviii) (xxxvii) 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyrazin-2-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (xlii) (xxxix) N-[4-Chloro-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide;
- (xlvi) (xl) N-{3-[4-(4-Methoxy-phenyl)-thiazol-2-ylamino]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide;
- (xlvii) (xlii) 4-(4-Methyl-piperazin-l-ylmethyl)-N-{4-methyl-3-[4-(3-trifluoromethyl-phenyl)-thiazol-2-ylamino]-phenyl}-benzamide;
- (xlviii) (xliii) N-{4-Methyl-3-[4-(3-nitro-phenyl)-thiazol-2-ylamino]-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide;
- (xlix) (xliv) N-{3-[4-(2,5-Dimethyl-phenyl)-thiazol-2-ylamino]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide;
- (1) (xlv) N-{3-[4-(4-Chloro-phenyl)-thiazol-2-ylamino]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide;
- (li) (xlvi) 3-Bromo-4-methyl-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (lii) (xlvii) 4-Fluoro-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (liii) (xlviii) 3,5-Dibromo-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-piperidin-1-ylmethyl-benzamide;
- (liv) (xlix) N-{3-[4-(3-Fluoro-phenyl)-thiazol-2-ylamino]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide;
- (lv) (l) N-{ 3-[4-(3-Methoxy-phenyl)-thiazol-2-ylamino]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide;

- (lvi) (li) N-{3-[4-(2-Fluoro-phenyl)-thiazol-2-ylamino]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide;
- (lvii) (lii) 4-Cyano-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (lviii) (liii) 4-Fluoro-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (lix) (liv) 1-(2-Fluoro-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea;
- (lx) 1-(2-Chloro-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea;
- (lxi) (lvi) 1-(3-Fluoro-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea;
- (Ivii) 1-[4-Methyl-3-(4-pyridin 3-yl-thiazol-2-ylamino) phenyl]-3-p-tolylurea
- (lxiii) (lviii) 3-Bromo-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (lix) N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-(thiophene-2-sulfonylamino)-benzamide;
- (lxv) (lx) 3-Fluoro-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (lxvi) (lxi) N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-pyridin-4-yl-benzamide;
- (lxvii) (lxii) 4-Dimethylamino-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (lxviii) (lxiii) 2-Fluoro-5-methyl-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (lxiv) 4-tert-Butyl-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;

- (lxx) (lxv) 4-Isopropoxy-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylmethyl)-phenyl]-benzamide;
- (lxxi) (lxvi) Benzo[1,3]dioxole-5-carboxylic acid [4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylmethyl)-phenyl]-amide;
- (lxxii) (lxvii) N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-3-(2-morpholin-4-yl-ethoxy)-benzamide;
- (lxxiii) (lxviii) N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylmethyl)-phenyl]-4-pyridin-4-yl-benzamide;
- (lxxiv) (lxix) 3-Cyano-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (lxxv) (lxx) 2-Fluoro-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;
- (lxxi) (lxxi) 4-Aminomethyl-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (lxxii) 3-Methoxy-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylmethyl)-phenyl]-benzamide;
- (lxxiii) 4-(4-Methyl-piperazin-1-yl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylmethyl)-phenyl]-benzamide;
- (lxxix) (lxxiv) Biphenyl-3-carboxylic acid [4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-amide;
- (lxxx) (lxxv) N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]isonicotinamide
- (lxxxi) (lxxvi) 2,6-Dichloro-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-isonicotinamide;
- (lxxxii) (lxxvii) 3,5-Dibromo-4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (lxxxiii) (lxxviii) 3-Fluoro-4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;

- (lxxiv) (lxxix) 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylmethyl)-phenyl]-3-trifluoromethyl-benzamide;
- (lxxx)(lxxx) 2,3,5,6-Tetrafluoro-4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (lxxxi) N-{3-[4-(4-Fluoro-phenyl)-thiazol-2-ylamino]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide;
- (lxxxii) 3-Bromo-4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (lxxxiii) 3-Chloro-4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (1xxxix) (1xxxiv) 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-4-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (xe) (lxxxv) N-{3-[4-(4-Cyano-phenyl)-thiazol-2-ylamino]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide;
- (xci) (lxxxvi) 4-[1-(4-Methyl-piperazin-1-yl)-ethyl]-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylmethyl)-phenyl]-benzamide;
- (xeii) (lxxxvii) 4-(1-Methoxy-ethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylmethyl)-phenyl]-benzamide;
- (xeiii) (lxxxviii) N-{4-Methyl-3-[4-(5-methyl-pyridin-3-yl)-thiazoi-2-ylamino]-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide;
- (xeiv) (lxxxix) 3-Iodo-4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylmethyl)-phenyl]-benzamide;
- (xev) (xc) 3,5-Dibromo-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-[(3-morpholin-4-yl-propylamino)-methyl]-benzamide;
- (xevi) (xci) 3-Dimethylamino-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;
- (xevii) (xcii) 3-(4-Methyl-piperazin-1-yl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide;

- (xeviii)(xciii) N-[4-Methyl-3-(4-pyridin-3-yI-thiazol-2-ylamino)-phenyl]-3-morpholin-4-yl-benzamide;
- (xeix) (xciv) Cyclohexanecarboxylic acid [4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylmethyl)-phenyl]-amide;
- (c) (xcv) 5-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenylcarbamoyl]-pentanoic acid ethyl ester;
- (lxii) (xevi) 1 Methyl-cyclohexanecarboxylic acid [4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylmethyl)-phenyl]-amide;
- (lxiii) (xevii) 4-tert-Butyl-eyelohexaneearboxylic acid [4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-amide;
- (ciii) (xcviii) (N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-morpholin-4-yl-butyramide;
- (civ) (xcix) [4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-carbamic acid isobutyl ester; and
- (ev) (c) 2-(2-methyl-5-tert-butoxycarbonylamino)phenyl-4-(3-pyridyl)-thiazole.
- 62. (Currently Amended) A compound according to claim 1 of the following formula:

wherein R is H or a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom selected from the group consisting of

halogen or a nitrogen atom or bearing at least one nitrogen group; a cycloalkyl, an aryl or heteroaryl group optionally substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with an at least one heteroatom selected from the group consisting of a halogen or a nitrogen atom, or bearing at least one nitrogen group.

63. (Currently Amended) A compound according to claim 1 of the following formula:

wherein R is H or a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom selected from the group consisting of a halogen or a nitrogen atom, or bearing at least one nitrogen group; a cycloalkyl, an aryl or heteroaryl group optionally substituted with an at least one heteroatom selected from nitrogen; a halogen selected from I, Cl, Br and F or bearing at least one nitrogen group; or a cycloalkyl, an aryl or heteroaryl group optionally substituted with a cycloalkyl, an aryl or heteroaryl group optionally substituted with an at least one heteroatom selected from nitrogen; a halogen selected from I, Cl, Br and F or bearing at least one nitrogen group;

heteroaryl optionally substituted with an at least one heteroatom selected from the group consisting of a halogen or a nitrogen atom, or bearing at least one nitrogen group; or a -CO-

R or a -CO-NRR' group, wherein R and R' are independently chosen from H, an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom selected from the group consisting of a halogen or a nitrogen atom, or bearing at least one nitrogen group.

64. (Currently Amended) A compound according to claim 1 of the following formula:

wherein R is H or a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom selected from the group consisting of a halogen or a nitrogen atom, or bearing at least one nitrogen group; a cycloalkyl, aryl or heteroaryl group optionally substituted with an at least one heteroatom selected from the group consisting of a halogen or a nitrogen atom, or bearing at least one nitrogen group; or an alkyl, cycloalkyl, aryl or heteroaryl group substituted by a alkyl, cycloalkyl, aryl or heteroaryl group optionally substituted with an at least one heteroatom selected from the group consisting of a halogen or a nitrogen atom, or bearing at least one nitrogen group;

heteroaryl group optionally substituted with an at least one heteroatom selected from the group consisting of a halogen or a nitrogen atom, or bearing at least one nitrogen group;

or a -CO-R or a -CO-NRR' group, wherein R and R' are independently chosen from H or an aryl heteroaryl, alkyl and cycloalkyl group optionally substituted with at least one heteroatom selected from the group consisting of a halogen or a nitrogen atom or bearing at least one nitrogen group.

65. (Previously Presented) A compound according to claim 1 of the following formula:

wherein R is H or a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom, or bearing at least one nitrogen group;

heteroatom selected from the group consisting of a halogen or a nitrogen atom, or bearing at least one nitrogen group; or an alkyl, cycloalkyl, aryl or heteroaryl group substituted by a alkyl, cycloalkyl, aryl or heteroaryl group optionally substituted with an at least one heteroatom selected from the group consisting of a halogen or a nitrogen atom, or bearing at least one nitrogen group;

a sulfonyl or a -SO2-R" group wherein R" is an alkyl, cycloalkyl, aryl or heteroaryl group optionally substituted with an at least one heteroatom selected from the group

consisting of a halogen or a nitrogen atom, or bearing at least one nitrogen group; or a -CO-R or a -CO-NRR' group, wherein R and R' are independently chosen from H or an aryl heteroaryl, alkyl and cycloalkyl group optionally substituted with at least one heteroatom selected from the group consisting of a halogen or a nitrogen atom or bearing at least one nitrogen group.

66. (Currently Amended) A compound according to claim 1 of the following formula:

wherein R is H or a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom selected from the group consisting of a halogen or a nitrogen atom or bearing at least one nitrogen group; a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom selected from the group consisting of a halogen or a nitrogen atom, or bearing at least one nitrogen group; or a cycloalkyl, an aryl or heteroaryl group substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with an at least one heteroatom selected from the group consisting of a halogen or a nitrogen atom, or bearing at least one nitrogen group.

67. (Currently Amended) A compound according to claim 1 of formula II:

FORMULA II

wherein X is R or NRR' and wherein R and R' are independently chosen from H, an aryl, an heteroaryl, an alkyl and a cycloalkyl group optionally substituted with at least one heteroatom selected from the group consisting of a halogen or a nitrogen atom, and optionally bearing at least one nitrogen group; or an aryl, an heteroaryl, an alkyl and a cycloalkyl group substituted with an aryl, an heteroaryl, an alkyl and a cycloalkyl group optionally substituted with at least one heteroatom selected from the group consisting of a halogen or a nitrogen atom, and optionally bearing at least one nitrogen group,

R² is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;

R³ is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;

R⁴ is halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;

R⁵ is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;

R⁶ is one of the following:

- (i) an aryl group or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl, and alkoxy;
- (ii) a heteroaryl group such as a 2, 3, or 4-pyridyl group, which may additionally bear any combination of one or more substituents;
- (iii) a five-membered ring aromatic heterocyclic group such as for example 2-thienyl, 3-thienyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, which may additionally bear any combination of one or more substituents.
- 68. (Previously Presented) A compound according to claim 67 selected from the group consisting of:
 - (i) 1-(4-Methoxy-phenyl)-3-[4-methyl-3-(4-pyridin-3-yI-thiazol-2-ylamino)-phenyl]-urea;
 - (ii) 1-(4-Bromo-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea;
 - (iii) 1-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-3-(4-trifluoromethyl-phenyl)-urea;
 - (iv) 1-(4-Fluoro-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea;
 - (v) 1-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-3-(3,4,5-trimethoxy-phenyl)-urea;
 - (vi) 4-{3-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-ureido}-benzoic acid ethyl ester;

- (vii) 1-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-3-thiophen-2-ylurea;
- (viii) 1-Cyclohexyl-1-(N-Cyclohexyl-formamide)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea;
- (ix) 1-(2,4-Dimethoxy-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea;
- (x) 1-(2-Iodo-phenyl)-1-(N-(2-Iodo-phenyl)-formamide)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea;
- (xi) 1-(3,5-Dimethyl-isoxazol-4-yl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea;
- (xii) 1-(2-Iodo-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea;
- (xiii) 1-(4-Difluoromethoxy-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea; and
- (xiv) and 1-(4-Dimethylamino-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea.
- 69. (Previously Presented) A compound according to claim 67, wherein X is a substituted alkyl, aryl or heteroaryl group bearing a nitrogen group represented by the structures (a)-(f) shown below:

wherein the wavy line corresponds to the point of attachment to core structure of formula II.

- 70. (Previously Presented) A compound according to claim 67, wherein X is group (d) and R^6 is a 3-pyridyl group.
- 71. (Previously Presented) A compound according to claim 67, wherein X is group (d) and R^4 is a methyl group.
- 72. (Previously Presented) A compound according to claim 67, wherein X is group (d) and R² and/or R³ and/or R⁵ is H.
- 73. (Previously Presented) A compound according to claim 1, wherein R^6 is a 3-pyridyl group and R^4 is a methyl group.
- 74. (Previously Presented) A compound according to claim 1, wherein R^6 is a 3-pyridyl group and R^2 and/or R^3 and/or R^5 is H.
- 75. (Previously Presented) A compound according to claim 1, wherein R² and/or R³ and/or R⁵ is H and R⁴ is a methyl group.
- 76. (Previously Presented) A compound according to claim 1, wherein R² and/or R³ and/or R⁵ is H, R⁴ is a methyl group and R⁶ is a 3-pyridyl group.
 - 77. (Canceled).
- 78. (Previously Presented) The compound of Claim 1 which is: 4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-4-yl-thiazol-2-ylamino)-phenyl]-benzamide.
- 79. (Previously Presented) The compound of Claim 1 which is: N-{3-[4-(4-cyano-phenyl)-thiazol-2-ylamino]}-4-methyl-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide.

- 80. (Previously Presented) The compound of claim 1 which is: 4-(4-methyl-piperazin-1-yl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide.
- 81. (Previously Presented) The compound of claim 1 which is: 4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide.